Secondary endpoints of the Vibrance-3 study are changes in the Idiopathic Hypersomnia Severity Scale ... also being developed for the treatment of narcolepsy type 1 and type 2.

NGENū CRO, a specialist Contract Research Organization with deep expertise in the complex field of sleep medicine, is pleased ...

Last year, Alkermes announced positive topline data from the narcolepsy type 2 (NT2) and idiopathic hypersomnia (IH) cohorts of a Phase Ib trial of ALKS 2680. Give your business an edge with our ...

DUBLIN, April 1, 2025 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced the initiation of Vibrance-3, a phase 2 clinical study evaluating the safety and efficacy of ALKS 2680 compared to ...

“The high rate of idiopathic hypersomnia (IH) diagnosis underscores the challenges with distinguishing between narcolepsy and IH based upon current testing. These findings also revealed insights ...